Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Otolaryngol Head Neck Surg. 2023 Sep;169(3):734-737. doi: 10.1002/ohn.280. Epub 2023 Jan 30.
Access to cochlear implantation can be restricted by financial burden, and little is known about the extent to which cochlear implant (CI) devices prices may vary between hospitals or manufacturers. We performed a cross-sectional analysis of private payer-negotiated prices for CI devices. In total, 161 hospitals were analyzed. Prices varied widely across hospitals and between payers. Despite clinical equipoise between manufacturers with regards to CI user outcomes, significant differences in prices were identified, with higher prices for MED-EL ($38,478 ± 2633) than for Cochlear Ltd. ($34,150 ± 2418, p < .001). Markup analysis for Cochlear Ltd. devices revealed a mean 58.5% ± 7.4% markup in excess of the company's average sales price ($24,649). Negotiated prices were also at least $5000 lower when all 3 brands were offered at the same center (p < .05). Further research examining the influence of patient outcomes and hospital volume on prices are needed.
人工耳蜗植入的可及性可能受到经济负担的限制,对于医院或制造商之间人工耳蜗(CI)设备价格的差异程度知之甚少。我们对私人支付者协商的 CI 设备价格进行了横断面分析。总共分析了 161 家医院。价格在医院之间和支付者之间差异很大。尽管制造商在 CI 用户结果方面具有临床均势,但价格存在显著差异,MED-EL 的价格($38,478 ± 2633)高于 Cochlear Ltd.($34,150 ± 2418,p <.001)。对 Cochlear Ltd. 设备的加价分析显示,超过公司平均销售价格($24,649)的平均加价幅度为 58.5%±7.4%。当同一中心提供所有 3 个品牌时,协商价格至少低 5000 美元(p <.05)。需要进一步研究患者结果和医院数量对价格的影响。